132 related articles for article (PubMed ID: 19121291)
1. Efficient lowering of triglyceride levels in mice by human apoAV protein variants associated with hypertriglyceridemia.
Vaessen SF; Sierts JA; Kuivenhoven JA; Schaap FG
Biochem Biophys Res Commun; 2009 Feb; 379(2):542-6. PubMed ID: 19121291
[TBL] [Abstract][Full Text] [Related]
2. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism.
Henneman P; Schaap FG; Havekes LM; Rensen PC; Frants RR; van Tol A; Hattori H; Smelt AH; van Dijk KW
Atherosclerosis; 2007 Jul; 193(1):129-34. PubMed ID: 16777114
[TBL] [Abstract][Full Text] [Related]
3. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.
Schaap FG; Rensen PC; Voshol PJ; Vrins C; van der Vliet HN; Chamuleau RA; Havekes LM; Groen AK; van Dijk KW
J Biol Chem; 2004 Jul; 279(27):27941-7. PubMed ID: 15090553
[TBL] [Abstract][Full Text] [Related]
4. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.
Vaessen SF; Dallinga-Thie GM; Ross CJ; Splint LJ; Castellani LW; Rensen PC; Hayden MR; Schaap FG; Kuivenhoven JA
J Lipid Res; 2009 May; 50(5):880-4. PubMed ID: 19141870
[TBL] [Abstract][Full Text] [Related]
5. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.
Shu X; Nelbach L; Weinstein MM; Burgess BL; Beckstead JA; Young SG; Ryan RO; Forte TM
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2504-9. PubMed ID: 20966404
[TBL] [Abstract][Full Text] [Related]
6. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding.
Dorfmeister B; Zeng WW; Dichlberger A; Nilsson SK; Schaap FG; Hubacek JA; Merkel M; Cooper JA; Lookene A; Putt W; Whittall R; Lee PJ; Lins L; Delsaux N; Nierman M; Kuivenhoven JA; Kastelein JJ; Vrablik M; Olivecrona G; Schneider WJ; Heeren J; Humphries SE; Talmud PJ
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1866-71. PubMed ID: 18635818
[TBL] [Abstract][Full Text] [Related]
7. Rare APOA5 mutations--clinical consequences, metabolic and functional effects: an ENID review.
Talmud PJ
Atherosclerosis; 2007 Oct; 194(2):287-92. PubMed ID: 17222847
[TBL] [Abstract][Full Text] [Related]
8. In vivo characterization of human APOA5 haplotypes.
Ahituv N; Akiyama J; Chapman-Helleboid A; Fruchart J; Pennacchio LA
Genomics; 2007 Dec; 90(6):674-9. PubMed ID: 17936576
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.
Merkel M; Loeffler B; Kluger M; Fabig N; Geppert G; Pennacchio LA; Laatsch A; Heeren J
J Biol Chem; 2005 Jun; 280(22):21553-60. PubMed ID: 15774484
[TBL] [Abstract][Full Text] [Related]
10. The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels.
Palmen J; Smith AJ; Dorfmeister B; Putt W; Humphries SE; Talmud PJ
Biochim Biophys Acta; 2008; 1782(7-8):447-52. PubMed ID: 18395529
[TBL] [Abstract][Full Text] [Related]
11. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
van Dijk KW; Rensen PC; Voshol PJ; Havekes LM
Curr Opin Lipidol; 2004 Jun; 15(3):239-46. PubMed ID: 15166778
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study.
Ariza MJ; Sánchez-Chaparro MA; Barón FJ; Hornos AM; Calvo-Bonacho E; Rioja J; Valdivielso P; Gelpi JA; González-Santos P
BMC Med Genet; 2010 Apr; 11():66. PubMed ID: 20429872
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Dorfmeister B; Brandlhofer S; Schaap FG; Hermann M; Fürnsinn C; Hagerty BP; Stangl H; Patsch W; Strobl W
Diabetologia; 2006 Jun; 49(6):1324-32. PubMed ID: 16570166
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.
Grosskopf I; Baroukh N; Lee SJ; Kamari Y; Harats D; Rubin EM; Pennacchio LA; Cooper AD
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2573-9. PubMed ID: 16166565
[TBL] [Abstract][Full Text] [Related]
15. The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.
Martinelli N; Trabetti E; Bassi A; Girelli D; Friso S; Pizzolo F; Sandri M; Malerba G; Pignatti PF; Corrocher R; Olivieri O
Atherosclerosis; 2007 Apr; 191(2):409-17. PubMed ID: 16682041
[TBL] [Abstract][Full Text] [Related]
16. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice.
Baroukh N; Bauge E; Akiyama J; Chang J; Afzal V; Fruchart JC; Rubin EM; Fruchart-Najib J; Pennacchio LA
Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1297-302. PubMed ID: 15117734
[TBL] [Abstract][Full Text] [Related]
17. Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients.
Pruneta-Deloche V; Ponsin G; Groisne L; Fruchart-Najib J; Lagarde M; Moulin P
Atherosclerosis; 2005 Aug; 181(2):403-5. PubMed ID: 16039297
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein lipase activity determined in vivo is lower in carriers of apolipoprotein A-V gene variants 19W and -1131C.
Kovář J; Adámková V
Physiol Res; 2008; 57(4):555-561. PubMed ID: 17705673
[TBL] [Abstract][Full Text] [Related]
19. Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291).
Sharma V; Witkowski A; Witkowska HE; Dykstra A; Simonsen JB; Nelbach L; Beckstead JA; Pullinger CR; Kane JP; Malloy MJ; Watson G; Forte TM; Ryan RO
Arterioscler Thromb Vasc Biol; 2014 Oct; 34(10):2254-60. PubMed ID: 25127531
[TBL] [Abstract][Full Text] [Related]
20. The influence of the S19W SNP of the APOA5 gene on triglyceride levels in southern Brazil: interactions with the APOE gene, sex and menopause status.
De Andrade FM; Maluf SW; Schuch JB; Voigt F; Barros AC; Lucatelli JF; Hutz MH
Nutr Metab Cardiovasc Dis; 2011 Aug; 21(8):584-90. PubMed ID: 20304614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
